September 14, 2005 In a surprising move, an FDA advisory panel voted to recommend Tarceva to treat pancreatic cancer. The drug is the result of a collaboration between OSI Pharma and Genentech, and it will be administered alongside Gemzar from Lilly. Here’s the kicker: the drug extended the median survival for just 12 days. At the same time, the FDA panel did not recommend Xinlay from Abbott Labs, a treatment for advanced prostate cancer. Both had Phase III tests that produced ambiguous data. We look at the difference between the two...
